Who is sponsoring NCT03879876?

NCT03879876 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT03879876?

Interventions in NCT03879876: Human T Lymphoid Progenitor (HTLP) injection.

What condition does NCT03879876 study?

NCT03879876 studies Pediatric Patients, Any Type of Severe Combined Immunodeficiency (SCID), Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Is NCT03879876 still recruiting?

NCT03879876 is currently status unknown. Last updated 27 September 2022.

Last reviewed 2022-09-27 · How we verify

NCT03879876: HTLP Necker

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients

Status unknown Phase 1, PHASE2 Last updated 27 September 2022

What this trial tests

Phase 1, PHASE2 trial testing Human T Lymphoid Progenitor (HTLP) injection in Pediatric Patients in 12 participants. Status unknown.

Timeline

13 May 2020

Primary endpoint
3 September 2023

3 June 2025

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	13 May 2020
Primary completion	3 September 2023
Estimated completion	3 June 2025
Sites	1 location across France

Drugs / interventions tested

Human T Lymphoid Progenitor (HTLP) injection — full drug profile →

Conditions studied

Pediatric Patients — all drugs for Pediatric Patients →
Any Type of Severe Combined Immunodeficiency (SCID) — all drugs for Any Type of Severe Combined Immunodeficiency (SCID) →
Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — all drugs for Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 2 to 18, any sex, with Pediatric Patients or Any Type of Severe Combined Immunodeficiency (SCID). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions.
Yanir A, Schulz A, Lawitschka A, Nierkens S, et al · · 2021 · cited 35× · PMID 35087775 · DOI 10.3389/fped.2021.786017
Physioxia enhances T-cell development ex vivo from human hematopoietic stem and progenitor cells.
Shin DY, Huang X, Gil CH, Aljoufi A, et al · · 2020 · cited 15× · PMID 32761664 · DOI 10.1002/stem.3259
A DL-4- and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors.
Moirangthem RD, Ma K, Lizot S, Cordesse A, et al · · 2021 · cited 11× · PMID 34117371 · DOI 10.1038/s41423-021-00706-8
Stem cell therapies in the clinic.
Acharya S, Shaha S, Bibbey MG, Mukherji M, et al · · 2025 · cited 3× · PMID 40385529 · DOI 10.1002/btm2.70000
T-Cell Progenitors As A New Immunotherapy to Bypass Hurdles of Allogeneic Hematopoietic Stem Cell Transplantation.
Gaudeaux P, Moirangthem RD, Bauquet A, Simons L, et al · · 2022 · cited 3× · PMID 35874778 · DOI 10.3389/fimmu.2022.956919
T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all.
Gaudeaux P, Moirangthem RD, Paillet J, Martin-Corredera M, et al · · 2022 · PMID 36180781 · DOI 10.1038/s41423-022-00927-5

Verify or expand the search:

Other recruiting trials for Pediatric Patients

Currently open trials in the same condition.

NCT06984276 — Ultrasound Guided Bilateral Pectoral Nerve Block Versus Bilateral Transverse Thoracic Plane Block In Pediatric Patients · NA · recruiting
NCT07408037 — Preoperative Gamified Breathing Exercise on Anxiety and Delirium in Children. · NA · recruiting
NCT05716243 — Nociception Level Index as a Verbal Tool of Pain in Children · NA · active not recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03879876 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 27 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03879876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing